Scholarlink

Waking up to the scientific world’s advancements through its own miracles, it still relies on the ancient methods for many therapeutic studies and uses the medicinal plants for their impeccable results, where the World Health Organization (WHO) makes a statement that up to 80% of the developing countries use traditional medicines for the treatment of many diseases. The drugs and health products are mostly from the secondary metabolites (majorly polyphenols, alkaloids, and terpenoids) of the medicinal plants. Photobiomodulation and light therapy are the therapy techniques used non-invasively to treat many diseases, including Alzheimer. The light is not only used in treatments of humans, but it is also a major component of the medicinal plant’s growth, marking the photoperiod (consisting of the quality, intensity, and duration of light), which marks the differential secondary metabolites. The flavonoids, plant polyphenols, are the major secondary metabolites used in Alzheimer’s disease (AD) treatment, which are found to be increased using UV-B in species like Artemisia annua, Prunella vulgaris, Withania somnifera, and Ixeris dentata and through blue light in species like Ocimum basilicum and Rodiola imbricata. Curcumin, a phenolic compound from Curcuma longa supplementation, is found to increase the neuroprotective action and is used in AD treatment. Some of the secondary metabolites from plants, phenolic acids like gallic acid, rosmarinic acid, and salvianolic acid B; flavonoids like luteolin, quercetin, myricetin, dihydromyricetin, fisetin, and silibinin; and curcumin are found to inhibit the amyloid beta fibrillogenesis and are used in the treatment of AD through thioflavin T assays showing the comparisons with thioflavin T and amyloid beta intensities, thus making the use of inhibiting properties of the secondary metabolites to function as a perfect therapy for AD and related diseases. This chapter will delve deeper into the role of medicinal plant-derived secondary metabolites and the influence of light-based modulation in enhancing their therapeutic potential, with a specific focus on their application in the treatment of AD.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Photo-Secondary Metabolites as a Potential Therapeutic Gateway for Alzheimer’s Disease Management

  • 章节

  • 发表日期：

    2026年

查看全文
  • Divya Sri Kathiresan,
  • Vinayaga Moorthi Puthamohan,
  • Sivamani Ganesan,
  • Arun Nagendran N.

摘要

Waking up to the scientific world’s advancements through its own miracles, it still relies on the ancient methods for many therapeutic studies and uses the medicinal plants for their impeccable results, where the World Health Organization (WHO) makes a statement that up to 80% of the developing countries use traditional medicines for the treatment of many diseases. The drugs and health products are mostly from the secondary metabolites (majorly polyphenols, alkaloids, and terpenoids) of the medicinal plants. Photobiomodulation and light therapy are the therapy techniques used non-invasively to treat many diseases, including Alzheimer. The light is not only used in treatments of humans, but it is also a major component of the medicinal plant’s growth, marking the photoperiod (consisting of the quality, intensity, and duration of light), which marks the differential secondary metabolites. The flavonoids, plant polyphenols, are the major secondary metabolites used in Alzheimer’s disease (AD) treatment, which are found to be increased using UV-B in species like Artemisia annua, Prunella vulgaris, Withania somnifera, and Ixeris dentata and through blue light in species like Ocimum basilicum and Rodiola imbricata. Curcumin, a phenolic compound from Curcuma longa supplementation, is found to increase the neuroprotective action and is used in AD treatment. Some of the secondary metabolites from plants, phenolic acids like gallic acid, rosmarinic acid, and salvianolic acid B; flavonoids like luteolin, quercetin, myricetin, dihydromyricetin, fisetin, and silibinin; and curcumin are found to inhibit the amyloid beta fibrillogenesis and are used in the treatment of AD through thioflavin T assays showing the comparisons with thioflavin T and amyloid beta intensities, thus making the use of inhibiting properties of the secondary metabolites to function as a perfect therapy for AD and related diseases. This chapter will delve deeper into the role of medicinal plant-derived secondary metabolites and the influence of light-based modulation in enhancing their therapeutic potential, with a specific focus on their application in the treatment of AD.